|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 63.50 GBX | 0.00% |
|
0.00% | -21.12% |
| 04-27 | Arecor Therapeutics plc Auditor Raises 'Going Concern' Doubt | CI |
| 04-27 | Arecor Therapeutics plc, 2025 Earnings Call, Apr 23, 2026 |
Company Valuation: Arecor Therapeutics plc
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Market Cap 1 | 111.3 | 73.48 | 55.89 | 27.75 | 30.39 | 23.98 | - |
| Change | - | -34% | -23.94% | -50.35% | 9.52% | -21.12% | - |
| Enterprise Value (EV) 1 | 93.02 | 60.68 | 49.14 | 24.49 | 24.36 | 22.66 | 27.18 |
| Change | - | -34.77% | -19.01% | -50.16% | -0.54% | -7% | 19.96% |
| P/E | -14.8x | -7.5x | -6.52x | -2.37x | - | - | - |
| PBR | - | 4.21x | 5.87x | 4.21x | 4.92x | 41.3x | - |
| PEG | - | -0.4x | 0.5x | -0.2x | - | - | - |
| Capitalization / Revenue | 96.1x | 30.6x | 12.2x | 5.49x | 9.61x | 27.3x | 22.8x |
| EV / Revenue | 80.3x | 25.3x | 10.7x | 4.85x | 7.7x | 25.8x | 25.9x |
| EV / EBITDA | -14.8x | -5.9x | -5.66x | -3.52x | -6.95x | -3.95x | -6.52x |
| EV / EBIT | -14.4x | -5.71x | -5.36x | -3.31x | 36.5x | -3.65x | -6.07x |
| EV / FCF | - | -5.48x | -8.2x | -2.67x | -9.9x | -4.86x | -22.7x |
| FCF Yield | - | -18.3% | -12.2% | -37.5% | -10.1% | -20.6% | -4.41% |
| Dividend per Share 2 | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - |
| EPS 2 | -0.27 | -0.32 | -0.28 | -0.31 | - | - | - |
| Distribution rate | - | - | - | - | - | - | - |
| Net sales 1 | 1.158 | 2.403 | 4.573 | 5.053 | 3.163 | 0.8785 | 1.05 |
| EBITDA 1 | -6.268 | -10.29 | -8.679 | -6.963 | -3.506 | -5.729 | -4.172 |
| EBIT 1 | -6.439 | -10.63 | -9.175 | -7.409 | 0.667 | -6.2 | -4.474 |
| Net income | -6.169 | -9.26 | -8.554 | -10.24 | - | - | - |
| Net Debt 1 | -18.32 | -12.81 | -6.752 | -3.257 | -6.032 | -1.32 | 3.203 |
| Reference price 2 | 4.0000 | 2.4000 | 1.8250 | 0.7350 | 0.8050 | 0.6350 | 0.6350 |
| Nbr of stocks (in thousands) | 27,835 | 30,618 | 30,627 | 37,757 | 37,757 | 37,757 | - |
| Announcement Date | 4/25/22 | 4/20/23 | 5/16/24 | 4/22/25 | 4/13/26 | - | - |
1GBP in Million2GBP
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | - | 25.79x | -3.95x | -.--% | 32.08M | |
| 31.99x | 5.69x | 17.6x | 1.03% | 46.06B | |
| -22.96x | 333.54x | -20.89x | -.--% | 38.91B | |
| 48.28x | 4.86x | 31.12x | -.--% | 35.57B | |
| 24.16x | 2.71x | 11.7x | -.--% | 33.13B | |
| 26.27x | 7.71x | 19.36x | 0.43% | 26.42B | |
| 31.03x | 5.02x | 22.85x | -.--% | 15.08B | |
| 24.17x | 2.07x | 9.1x | 1.09% | 14.08B | |
| 23.64x | 1.89x | 11.43x | -.--% | 12.81B | |
| Average | 23.32x | 43.25x | 10.92x | 0.28% | 24.68B | |
| Weighted average by Cap. | 22.08x | 62.30x | 11.81x | 0.33% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- AREC Stock
- Valuation Arecor Therapeutics plc
Select your edition
All financial news and data tailored to specific country editions
